|
|
 |
Human Gene Set: HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO
|
| Standard name | HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP |
|---|---|
| Systematic name | M40920 |
| Brief description | Genes up-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) (low antibody responders to treatment) after exposure to M-M-R II , time point 7Y |
| Full description or abstract | BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies. |
| Collection | C7: Immunologic Signature VAX: HIPC Vaccine Response |
| Source publication | Pubmed 27529750 Authors: Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA |
| Exact source | Table 1 |
| Related gene sets |
(show 4 additional gene sets from the source publication)
(show 29 gene sets from the same authors) |
| External links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/table/pone.0160970.t001/ |
| Filtered by similarity ? | |
| Source species | Homo sapiens |
| Contributed by | HIPC SIGNATURES (NIAID/HIPC SIGNATURES) |
| Source platform or identifier namespace |
HUMAN_GENE_SYMBOL |
| Dataset references | |
| Download gene set | format: grp | gmt | xml | json | TSV metadata |
| Compute overlaps ? |
(show collections to investigate for overlap with this gene set)
|
| Compendia expression profiles ? |
NG-CHM interactive heatmaps (Please note that clustering takes a few seconds) Legacy heatmaps (PNG) |
| Advanced query | Further investigate these 14 genes |
| Gene families ? | Categorize these 14 genes by gene family |
| Show members |
(show 14 source identifiers mapped to 14 genes)
|
| Version history | 7.3: First Introduced. |
See MSigDB license terms here. Please note that certain gene sets have special access terms.
